Soluble guanylyl cyclase stimulation and phosphodiesterase‐5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct

Soluble guanylyl cyclase stimulation and phosphodiesterase‐5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct–ligated rats

Published:2020-01-12 Issue:10 Volume:8 Page:1174-1185
ISSN:2050-6406
Container-title:United European Gastroenterology Journal
language:en
Short-container-title:United European Gastroenterol. j.

Author:

Brusilovskaya Ksenia¹²³⁴⁵^ORCID,Königshofer Philipp¹²³⁴⁵^ORCID,Lampach Daniel¹²,Szodl Adrian¹²,Supper Paul¹²^ORCID,Bauer David¹²³,Beer Andrea⁶,Stift Judith⁶,Timelthaler Gerald⁷,Oberhuber Georg⁸,Podesser Bruno Karl⁹,Seif Martha¹²³,Zinober Kerstin¹²³,Rohr‐Udilova Nataliya¹²³,Trauner Michael¹,Reiberger Thomas¹²³⁴⁵^ORCID,Schwabl Philipp¹²³⁴⁵

Affiliation:

1. Division of Gastroenterology and HepatologyDepartment of Medicine IIIMedical University of ViennaViennaAustria

2. Vienna Hepatic Haemodynamic Lab (HEPEX)Medical University of ViennaViennaAustria

3. Christian‐Doppler Laboratory for Portal Hypertension and Liver FibrosisMedical University of ViennaViennaAustria

4. Ludwig Boltzmann Institute for Rare and Undiagnosed DiseasesViennaAustria

5. CeMM Research Center for Molecular Medicine of the Austrian Academy of SciencesViennaAustria

6. Department of PathologyMedical University of ViennaViennaAustria

7. The Institute of Cancer ResearchDepartment of Medicine IMedical University of ViennaViennaAustria

8. INNPATH Institute for PathologyInnsbruckAustria

9. Center for Biomedical ResearchMedical University of ViennaViennaAustria

Funder

Medizinische Universität Wien

Boehringer Ingelheim Stiftung

Medical Scientific Fund of the Mayor of the City of Vienna

Boehringer-Ingelheim

Publisher

Wiley

Subject

Gastroenterology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2050640620944140

Reference34 articles.

1. Expanding consensus in portal hypertension

2. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases

3. Molecular pathophysiology of portal hypertension

4. A molecular basis for nitric oxide sensing by soluble guanylate cyclase

5. The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension;Hepatobiliary & Pancreatic Diseases International;2024-02

2. Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study;Hepatology Communications;2023-10-27

3. Dysregulated Cyclic Nucleotide Metabolism in Alcohol-Associated Steatohepatitis: Implications for Novel Targeted Therapies;Biology;2023-10-10

4. Biased Quantification of Rat Liver Fibrosis—Meta-Analysis with Practical Recommendations and Clinical Implications;Journal of Clinical Medicine;2023-08-01

5. Hub genes, diagnostic model, and predicted drugs in systemic sclerosis by integrated bioinformatics analysis;Frontiers in Genetics;2023-07-12